Carisoprodol was designed to be safer than its predecessor, but it carries hidden risks.

Carisoprodol was designed to be safer than its predecessor, but it carries hidden risks.
Image: Intellect (generated)

In short: Developed in 1959 as a muscle relaxant with lower addiction potential than meprobamate, carisoprodol is now a Schedule IV controlled substance. While it effectively treats acute musculoskeletal pain, its rapid metabolism into addictive compounds and dangerous interactions with opioids have led to its withdrawal from markets across the globe.

Carisoprodol was created by Frank Berger at Wallace Laboratories as a structural analogue of meprobamate. By substituting a hydrogen atom with an isopropyl group, researchers hoped to improve muscle-relaxing properties while reducing the risk of overdose and dependence. However, clinical reality proved more complex. The drug is rapidly metabolized in the liver via the CYP2C19 enzyme into meprobamate, which reaches higher peak plasma levels than the parent drug itself. This conversion is central to its pharmacological profile, as meprobamate is a known addictive substance.

The drug’s mechanism is distinct from benzodiazepines. While it acts as a GABAA agonist, it does not prevent seizures and may actually increase the risk of them, particularly during withdrawal. Discontinuation after long-term use can trigger a severe syndrome mimicking alcohol withdrawal, including potentially lethal status epilepticus. Because of these risks, the drug is now heavily regulated. The European Union withdrew its approval in 2008, and the United States Drug Enforcement Administration placed it on Schedule IV in 2012.

Beyond its own risks, carisoprodol is frequently misused in combination with other substances. It is often paired with opioids and benzodiazepines—a combination colloquially known as the Holy Trinity—to potentiate sedative effects. This practice is notoriously dangerous, as it significantly increases the risk of respiratory depression and fatal overdose. Toxicology screens do not always detect the drug, which can complicate emergency medical responses. Consequently, health authorities in countries like Norway, Sweden, and Australia have either restricted or removed the medication from their markets due to persistent issues with diversion and dependence.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/science-carisoprodol.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…